Drug intelligence / Profile preview

quadrivalent live attenuated influenza vaccine (AstraZeneca)

Development stage: Approved
Lead developer: AstraZeneca
Modality: Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intranasal

Overview

Quadrivalent live attenuated influenza vaccine (LAIV4) is an intranasal vaccine containing weakened live influenza viruses that can replicate in the nasal passages to create an immune response without causing influenza illness. It provides protection against four strains of influenza viruses most likely to be circulating in a given season.

Brand names: FluMist
Other names: Live Attenuated Influenza Vaccine, Quadrivalent

Targets

Sia (Host cell sialic acid residues on respiratory epithelial glycoproteins/glycolipids)H1N1 (Influenza A virus H1N1)IBV-Yamagata (Influenza B virus Yamagata lineage)

Beyond the preview

Go deeper on quadrivalent live attenuated influenza vaccine (AstraZeneca).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on quadrivalent live attenuated influenza vaccine (AstraZeneca).